Exact Sciences: The Merger Vote is In, But What Are Insiders Really Doing?

The headline vote is a formality. Stockholders overwhelmingly approved the Abbott merger, with more than 99% of votes cast in favor. The board's deal is now a done deal, pending final regulatory clearances. The real story, however, is written in the filings, not the press release.

A clear vote of no confidence came on the advisory executive compensation proposal, which was not approved at the same meeting. That's a red flag. When insiders aren't aligned with the pay package tied to a mega-deal, it often signals they see little upside in the long-term. The $105 cash offer is a sure thing, but the real question is whether the company's own people believe it's a fair price for their future.

More telling is the institutional track record. While the merger vote passed, the smart money has been quietly exiting. Institutional ownership has been declining, with a net reduction of 1.66% in the last quarter. That's a steady, passive outflow from funds that are supposed to be the most informed investors. The lack of institutional accumulation-measured by a Fund Sentiment Score that shows no buying frenzy-suggests many whales see little reason to pile in ahead of the cash offer.

The bottom line is a lack of skin in the game. The merger vote is a rubber stamp. The real signal is the quiet departure of the smart money and the board's own skepticism on pay. When the people with the most to lose aren't buying, the alignment of interest is broken.

Insider Skin in the Game: Sales Over Stock Awards

The board's approval is a formality. The real test is what insiders do with their own money. And the filings show a clear pattern of selling while getting new grants.

Key executives, including the General Counsel and an Officer, sold significant shares in November 2025 at prices well below the $105 cash offer. James Herrmann sold 105,120 shares at $70.08 and Jacob Orville sold 375,000 shares at $75.00. These were not small, opportunistic trades. They were large, strategic exits at a fraction of the deal price. The message is simple: they see little reason to hold onto stock when a better offer is on the table.

Then, just weeks later, the same executives received new stock awards. On December 23, 2025, the General Counsel, Officer, CFO, and CEO all got fresh grants at a grant price of $0.00 per share. This is a classic dilution play. It gives them new equity with no cost, but it waters down the ownership of everyone else. It's a gift that costs the company nothing but increases the total shares outstanding.

The CEO, Kevin Conroy, is the most telling case. He received a new stock award in February 2025, but his last sale was in November 2025. He's not buying more stock; he's letting his existing holdings sit while he takes on new, zero-cost grants. This is a lack of skin in the game for the deal's future.

The thesis is clear. Insiders are selling while getting new grants. They are cashing out at a discount while the company hands them new shares for free. When the people with the most intimate knowledge of the company's value are exiting at a discount and then getting new grants, it suggests they see little upside in the long-term. The alignment of interest is broken.

Institutional Accumulation vs. The Whale Wallet

The smart money isn't betting against the deal. It's quietly exiting. Major institutional holders like Wellington Management and BlackRock have been reducing their positions significantly in recent filings. The largest institutional owner, Vanguard Group, has seen its allocation decrease by 1.56% over the last quarter. This isn't a panic sell; it's a steady, passive outflow from funds that are supposed to be the most informed investors.

The stock price tells the same story. It has been range-bound near $103, trading below the $105 cash offer and showing no significant accumulation ahead of the expected Q2 2026 close. The Fund Sentiment Score, which measures institutional buying pressure, shows no accumulation frenzy. In reality, the whales are trimming their wallets, not because it thinks the deal fails, but because it thinks the stock has nowhere to go but down to the offer price.

This lack of conviction is telling. When the largest holders aren't betting on the upside, it suggests they see little reason to pile in ahead of a sure thing. The stock is stuck in a holding pattern, reflecting a market that has already priced in the deal but sees no further catalyst. The bottom line is a lack of institutional skin in the game for the post-merger period. The smart money is waiting on the sidelines, not because it thinks the deal fails, but because it thinks the stock has nowhere to go but down to the offer price.

Catalysts and Risks: What to Watch for the Thesis

The deal is approved, but the real test is what happens next. The thesis of insider and institutional skepticism hinges on future actions, not past votes. Watch for two key catalysts in the final weeks before the expected Q2 2026 close.

First, monitor insider filings for any new sales or grants. The pattern is clear: executives sold at a discount and then received new zero-cost awards. The primary risk is that the deal closes as planned, validating the $105 price, but the insider sales suggest they saw a better exit earlier. If we see more large sales before the close, it would confirm the lack of skin in the game. Conversely, any significant buying by insiders would contradict the current narrative of skepticism.

Second, watch institutional 13F filings for any large, unexpected buys. The smart money has been quietly exiting, with a net reduction of 1.66% in the last quarter. The Fund Sentiment Score shows no accumulation frenzy. Any sudden, large institutional buying would signal a change in the whales' view and could spark a rally toward the offer price. The absence of such moves, however, would reinforce the thesis that the stock is stuck in a holding pattern, reflecting a market that has already priced in the deal but sees no further catalyst.

The bottom line is that the real signal is what insiders and institutions do next. The vote is a rubber stamp. The filings are the playbook.